Celiac, a Common Autoimmune Disease, May Not Be Caused by an Overactive Immune System

Using a new a new technology called the Cyton2 Cell Timer, researchers found that the immune system’s CD4 helper T cells were actually weaker.

Pedal to the Stock/Shutterstock

Your immune system may signal that celiac disease is coming long before you ever feel sick, and possibly even before you eat a single bite of gluten.

Celiac disease has long been attributed to an overactive immune response to gluten. However, a study recently published in Immunology and Cell Biology suggests there is a reduction in immune activity that starts much earlier and runs much deeper.

The research focused on a type of immune cell called CD4 helper T cells. These white blood cells are to immune cells what sergeants are to soldiers—they give orders and help coordinate the body’s immune response, fight infections, and support antibody production.

The surprise wasn’t that these cells were overactive. They were actually weaker, producing less of a key immune signal called interleukin-2, dividing more slowly, and less likely to survive. This pattern held regardless of sex, how recently someone was diagnosed, or how long they had been gluten-free.

“That suggests the changes [in the gut] may not be caused only by active inflammation or recent gluten exposure,” Dr. Jason Korenblit, a board-certified gastroenterologist at JustAnswer, who was not involved in the study, told The Epoch Times. “They may reflect a built-in immune tendency, likely influenced by genetics.”

Wired Differently From the Start

To detect these differences, researchers used a new technology called the Cyton2 Cell Timer and a method that briefly activates immune cells, then removes all signals to observe how the cells behave on their own. “Our assay is a bit like winding up a toy and letting it go to see how long it runs and what tricks it performs,” study author Dr. Vanessa Bryant said in a statement.

What that winding-and-releasing revealed is a property the researchers called immune momentum—a new scientific concept describing how long immune cells stay active after their initial trigger has stopped.

They found that CD4 helper cells were producing less of a key immune signal called interleukin-2, dividing more slowly, and less likely to survive.

“Gluten is still necessary to activate the disease,” Korenblit said, “but the immune system may already be wired to respond abnormally. That may help explain why celiac disease clusters in families and why it overlaps with other autoimmune diseases.”

From a gastroenterology standpoint, he said, this study is important because it supports the idea that celiac disease is not just a reaction to gluten in the gut. “It may also involve a deeper, baseline difference in how the immune system is programmed.”

A Window Into Autoimmune Disease

While the study focused on celiac disease, the researchers believe similar immune patterns might exist in other autoimmune conditions, which affect about five percent of the population.

Study author Jason Tye-Din believes the new testing model could eventually uncover hidden patterns across a range of autoimmune conditions, which affect roughly 5 percent of the population. “Although these helper cells aren’t always the main focus in autoimmune research, they may hold important clues to why disease develops in some people and not others,” Tye‑Din said in the statement.

The team is now investigating whether similar immune patterns exist in other autoimmune conditions and how early in life these differences appear.

The implications for early detection are significant, though experts urge caution about how quickly this could translate to clinical practice.

If future studies confirm that these immune patterns appear before symptoms or intestinal damage, testing immune cell behavior could identify high-risk individuals far earlier than is currently possible, Korenblit said.

This, he added, could be especially useful for first-degree relatives of people with celiac disease, children with celiac-associated genes, or patients with other autoimmune diseases.

“Earlier detection could allow closer monitoring, earlier antibody testing, nutritional assessment, and faster diagnosis once disease begins,” Korenblit said. “However, we would need larger, long-term studies following at-risk people over time before using this clinically.”